Cristina Queralt

Institut Català d'Oncologia
Country flagSpain
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Background Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease. The combination of 5‐Fluorouracil (5FU, a thymidylate synthase inhibitor) and irinotecan (a topoisomerase 1 inhibitor) is widely used in first‐line and subsequent treatments. This study aimed to identify novel therapeutic targets to enhance combinatorial therapy, improving treatment efficacy and durability of response. Methods We performed a loss‐of‐function screen using HT29 CRC cell line and a retroviral library containing 7296 shRNAs targeting 912 chromatin genes. Cells were then treated with 5FU and SN38 (the active metabolite of irinotecan) or left untreated for 4 weeks. Genes enriched in resistant clones were identified through next‐generation sequencing. Amongst candidate genes, PARG was selected for functional validation. Results CRISPR/Cas9‐mediated knockout (HT29 PARG‐KO) resulted in increased global poly(ADP‐ribosyl)ation after 5FU and SN38 treatment. PARG depletion led to reduced cell viability and increased apoptosis, particularly after 5FU exposure. Pharmacological PARG inhibition (PDD00017273) synergised with 5FU and SN38 across three CRC models (HT29, DLD1, HT115). In vivo, HT29 PARG‐KO xenografts were more sensitive to 5FU. Immunohistochemical analysis of 170 CRC patient tumours revealed that positive PARG expression correlated with poor response to 5FU + Irinotecan, increased liver metastases, and worse long‐term survival. Conclusions Our findings highlight PARG as a promising therapeutic target for CRC, where its inhibition enhances the efficacy of standard chemotherapy. Key points LOF screening identified PARG as a modulator of CRC response to FUIRI treatment. HT29 PARG‐KO cells showed increased PAR, DNA damage, apoptosis, and 5FU sensitivity. Pharmacological PARG inhibition synergised with 5FU and SN38 in CRC cell lines. HT29 PARG‐KO tumours exhibited increased sensitivity to 5FU treatment in vivo. PARG expression in CRC tumours correlated with poorer responses and patient survival.

Year:

2025

Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease. The combination of 5-Fluorouracil (5FU, a thymidylate synthase inhibitor) and irinotecan (a topoisomerase 1 inhibitor) is widely used in first-line and subsequent treatments. This study aimed to identify novel therapeutic targets to enhance combinatorial therapy, improving treatment efficacy and durability of response. We performed a loss-of-function screen using HT29 CRC cell line and a retroviral library containing 7296 shRNAs targeting 912 chromatin genes. Cells were then treated with 5FU and SN38 (the active metabolite of irinotecan) or left untreated for 4 weeks. Genes enriched in resistant clones were identified through next-generation sequencing. Among candidate genes, PARG was selected for functional validation. CRISPR/Cas9-mediated knockout (HT29 PARG-KO) resulted in increased global poly(ADP-ribosyl)ation after 5FU and SN38 treatment. PARG depletion led to reduced cell viability and increased apoptosis, particularly after 5FU exposure. Pharmacological PARG inhibition (PDD00017273) synergized with 5FU and SN38 across three CRC models (HT29, DLD1, HT115). In vivo , HT29 PARG-KO xenografts were more sensitive to 5FU. Immunohistochemical analysis of 170 CRC patient tumors revealed that positive PARG expression correlated with poor response to 5FU + Irinotecan, increased liver metastases, and worse long-term survival. Our findings highlight PARG as a promising therapeutic target for CRC, where its inhibition enhances the efficacy of standard chemotherapy.

Year:

2025

Background Reliable biomarkers for precision medicine in metastatic colorectal cancer (mCRC) are needed. Blood biomarkers like chemokines may offer insights into overall tumor burden, yet, few prospective studies explore chemokine dynamics during treatment. This study investigates the behavior of a chemokine panel in mCRC patients during first-line oxaliplatin-based treatment, aiming to identify predictive and prognostic biomarkers. Methods Blood from oxaliplatin-treated mCRC patients was collected at three time points: before treatment (PRET), at response evaluation (EVAR), and at disease progression or last follow-up (LFUP). A custom 11-chemokine panel assessed serum chemokine levels by Luminex®, correlating them with treatment response, overall survival (OS), and progression-free survival (PFS) using the Cox proportional hazards models with the inverse probability weighting (IPW) approach. Additionally, immune system-associated gene expression was studied by Nanostring® in 15 primary tumor samples and correlated with CXCL13 expression, OS, and PFS. In silico analysis of 119 liver metastases from CRC patients, post neoadjuvant oxaliplatin-based treatment or untreated, evaluated CXCL13 expression’s correlation with immune cell infiltration, tertiary lymphoid structure (TLS) presence, OS, and PFS. Additionally, CXCL13 dynamics was studied by ELISA in 36 mCRC patients from the METIMMOX study control arm. Results Responders exhibited increased CXCL13 at EVAR, contrasting with non-responders whose levels decreased at EVAR and LFUP. Increased CXCL13 independently associated with improved PFS (median 14.5 vs. 8.9 months; HR = 0.34, p = 0.003) and OS (median 39.7 vs. 15.3 months; HR = 0.34, p = 0.003). CXCL13 expression correlated positively with an immunogenic tumor microenvironment, increased B cells, T cells (mainly CD8+) and enhanced OS. In silico , higher CXCL13 expression associated significantly with increased immune infiltration and improved OS. High CXCL13 expression was linked to the presence of TLSs, also associated with enhanced OS, especially in neoadjuvant-treated patients. Similar trends were obtained using the METIMMOX cohort. Conclusion The increase of CXCL13 levels in peripheral blood and its association with the formation of TLSs within the metastatic lesions, emerges as a potential biomarker indicative of the therapeutic efficacy in metastatic CRC patients undergoing oxaliplatin-based treatment.

Year:

2024

Collaborators (7)

Clara Montagut Viladot

Head Gastrointestinal Cancer Section

Hospital del Mar

SPAIN
View details

Sonia Vanina Forcales

Professor of Immunology, Serra Húnter Programme

University of Barcelona

SPAIN
View details

Johannes Zuber

Senior Group Leader

Research Institute of Molecular Pathology

AUSTRIA
View details

Eva Musulen

Institut de Recerca Contra la Leucemia Josep Carreras

SPAIN
View details

Anna Esteve

Institut Català d'Oncologia

SPAIN
View details

Pilar Navarro

Investigadora Científica-Head of the " Cancer Molecular Targets" group

-

SPAIN
View details

Anne H. Ree

Oslo University Hospital

NORWAY
View details